Comprehensive Bibliography

1. ABRAXANE [prescribing information]. Los Angeles, Calif: Abraxis Oncology, a Division of Abraxis BioScience, Inc; May 2007.
2. Benigno BB, Hines JF. Phase II study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer. Presented at: 2006 American Society of Clinical Oncology Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 15033.
3. Bernacki RJ, Veith J, Pera P, et al. A novel nanoparticle albumin bound thiocolchicine dimer (nab-5404) with dual mechanisms of action on tubulin and topoisomerase-1: evaluation of in vitro and in vivo activity. Presented at: 96th American Association of Cancer Research Annual Meeting; April 16-20, 2005; Anaheim, Calif. Abstract 2390.
4. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol. 1999;75:25-33.
5. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of (mTOR) antagonists. Breast Cancer Res. 2004;6:219-224.
6. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19:569-577.
7. Damascelli B, Patelli GL, Lanocita R, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am J Roentgenol. 2003;181:253-260.
8. Damascelli B, Patelli GH, Lanocita R, et al. Intra-arterial paclitaxel in albumin nanoparticles controls squamous carcinoma at various sites. Proc Am Soc Clin Oncol. 2003;22. Abstract 2050.
9. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007). Cancer. 2001;92:2592-2602.
10. Data on file, DA-ABR-01. Abraxis BioScience, LLC
11. De T, Trieu V, Yim Z, et al. Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. Presented at: 98th American Association for Cancer Research Annual Meeting 2007; April 14-18, 2007; Los Angeles, California. Abstract 4719.
12. Desai N, Trieu V, Yang A, et al. Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus Taxotere. Presented at: 97th American Association of Cancer Research Annual Meeting; April 1-5, 2006; Washington, DC. Abstract 5438.
13. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor^®-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-1324.
14. Desai N, De T, Trieu V, Hawkins MJ, Soon-Shiong P. Nanoparticle albumin bound (nab) dimeric thiocolchicines nab-5404, nab-5800, and nab-5801: a comparative evaluation of antitumor activity vs Abraxane and Irinotecan. Presented at: 96th American Association of Cancer Research Annual Meeting; April 16-20, 2005; Anaheim, Calif. Abstract 3439.
15. Desai N, Trieu V, Hawkins M, et al. Improved effectiveness of nab-paclitaxel versus docetaxel in various xenografts as a function of HER2 and SPARC status. Presented at: 16th Symposium on Molecular Targets and Cancer Therapeutics; September 28-October 1, 2004; Geneva, Switzerland. Abstract 505.
16. Gradishar W, Krasnojon D, Cheporov S, et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Tex. Abstract 46.
17. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
18. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of non-small-cell lung cancer. Ann Oncol. 2006;17:1263-1268.
19. Greco A, et al. Albumin bound paclitaxel wkly+carboplatin: first-line therapy for advanced NSCLC. Proceedings of the Chemotherapy Foundation Symposium XXIV; November 12, 2006; New York, NY.
20. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353-361.
21. Hersh E, O'Day S, Gonzalez R, et al. Open-label multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma. Presented at: 41st American Society of Clinical Oncology Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 7558.
22. Ibrahim NK, Samuels B, Page R, et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23:6019-6026.
23. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-1044.
24. John TA, Vogel SM, Minshall RD, Ridge K, Tiruppathi C, Malik AB. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol. 2001;533:547-559.
25. Jones C, Mackay A, Grigoriadia A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004;64:3037-3045.
26. Makriyannis A, Guo J, Tian X. Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. Life Sci. 2005;77:1605-1611.
27. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol. 2006;100:437-438.
28. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer. 2005;6:361-364.
29. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(suppl 4):S55-S61.
30. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23:7785-7793.
31. Raspaglio G, Ferlini C, Mozzetti S, et al. Thiocolchicine dimers: a novel class of topoisomerase-1 inhibitors. Biochem Pharmacol. 2005;69:113-121.
32. Reynolds C, et al. Nab-paclitaxel/carboplatin/bevacizumab in advanced non-squamous NSCLC. Proceedings of the Chemotherapy Foundation Symposium XXIV; November 12, 2006; New York, NY.
33. Rizvi NA, Azzoli C, Miller V, et al. Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Presented at: 42nd American Society of Clinical Oncology 42nd Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 7105.
34. Schnitzer JE. Gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol. 1992;262:H246-H254.
35. Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol. 1992;263:H1872-H1879.
36. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136-4143.
37. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6:1140-1149.
38. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem. 1997;272:25968-25975.
39. Trieu V, Damascelli B, Soon-Shiong P, Desai P. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane). Presented at: 97th American Association of Cancer Research Annual Meeting; April 1-5, 2006; Washington, DC. Abstract 4477.
40. Trieu V, De T, Labao E, et al. Anti-angiogenic and antitumor activity of nanoparticle albumin bound (nab) thiocolchicine dimer (IDN5404) with a novel dual mechanism of action on tubulin and topoisomerase-1. Presented at: 97th American Association of Cancer Research Annual Meeting; April 1-5, 2006; Washington, DC. Abstract 3823.
41. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. Albumin update and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1512-L1522.
42. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72:267-272.